Associate Investigator
Institute for Cancer Research
Chinese Institutes for Medical Research, Beijing, China
Vice chief/Chief physician/Professor
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

Education
BS, Clinical Medicine, Xuzhou Medical University
MS, Internal Medicine, Xuzhou Medical University
MD/PhD, Internal Medicine, Peking university
Fellowship training, Academy of Military Medical Sciences

 

Pathogenesis, targeted therapy, and clinical translational research of acute leukemia
Mechanisms of immunotherapy and drug resistance in leukemia

 

Representative publications
Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, Xu G, Lu Y, Wei J, Mai W, Ye X, Meng H, Shen Y, Huang J, Yu W, Sun J, Sheng J, Yan X, Jin J, Zhu HH. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9(6):e415-e424.
Li K, Wang F, Yang ZN, Cui B, Li PP, Li ZY, Hu ZW, Zhu HH. PML-RARα interaction with TRIB3 impedes PPAR γ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020;10(22):10326-10340.
Zhu HH, Liu YR, Jia JS, Qin YZ, Zhao XS, Lai YY. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 2018;131(26):2987-2989.
Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871-879.
Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promelocytic leukemia. N Engl J Med. 2014;370(19):1864-6.